P632: Comparison of treatment-emergent adverse events of acalabrutinib and zanubrutinib in clinical trials in B-cell malignancies: A systemic review and meta-analysis

A review of 61 related trials involving 6,959 patients, treatment-emergent adverse events (TEAEs) for ibrutinib, acalabrutinib, and zanubrutinib were investigated. A total of 84 AEs were analyzed, and the incidence of all-grade and ≥ grade 3 AEs was lower with acalabrutinib and zanubrutinib. The authors provide a detailed comparison in the abstract between zanubrutinib and acalabrutinib for ≥ 3 AEs, including which agents result in more neutropenia, infections, and fatigue.